- Patients aged ≥80 years who received more aggressive therapy for SCLC had better survival than those who received chemotherapy alone, local therapy alone, or no treatment.
- Nearly one-third of patients did not receive treatment.
Why this matters
- Elderly patients are a growing population among SCLC cases, but data on treatment and outcomes are lacking, as they are rarely included in clinical trials.
- 146 patients from the Institutional Lung Cancer Database who were ≥80 years at SCLC diagnosis.
- Funding: None.
- 32% had limited-stage SCLC and 68% had extensive-stage disease.
- 30% of patients received no therapy, 44.5% received chemotherapy alone, 18.5% received chemotherapy plus radiotherapy and/or surgery (local therapy), and 7% received local therapy alone.
- Median OS for the entire cohort was 5.4 months.
- After multivariable analysis, disease stage (P=.011), performance score (P=.029), and treatment option (P<.0001 were significantly associated with os.>
- Median OS was 1.3 months without active therapy, 6 months with local therapy alone, 7.2 months with chemotherapy alone, and 14.4 months with chemotherapy plus local therapy.
- After multivariable analysis, only the treatment option remained significant for survival among patients with limited-stage (P=.0001) and extensive-stage (P<.0001 disease.>
- Retrospective study.